View Full Version : Bioheart buys stem cell license from Aventura group

02-17-2012, 04:34 PM
South Florida Business Journal by Brian Bandell, Senior Reporter
Date: Tuesday, February 14, 2012

Bioheart acquired the exclusive license to the Ageless Regenerative Institute's technique for extracting adipose (fat) stem cells from patients for use in heart treatments.

Sunrise-based Bioheart (OTCBB: BHRT) already holds the license to extract stem cells from muscle tissue for use in cardiology.

Kristin Comella, Bioheart chief scientific officer, said the muscular stem cells are best at regenerating muscle tissue in scarred parts of a damaged heart, while the adipose stem cells should be effective in rebuilding blood vessels.

“Ideally, if there were no regulatory limitations, you would use both cell types in the heart,” she said. “We use a catheter, so it is very targeted. You can visualize exactly where you are injecting.”

The license Bioheart bought from the Aventura-based Ageless Regenerative Institute covers the process used to extract the adipose stem cells, but any company or research organization can attempt to use multiple stem cell types for heart treatment. No company has secured U.S. Food and Drug Administration approval for this method yet. Comella said Bioheart is awaiting more funding so it can launch additional clinical trials.

“The Ageless adipose stem cell technology will allow us to broaden our portfolio of product candidates for cardiac patients,” Bioheart President and CEO Mike Tomas said in a news release. “We have successfully treated patients in Mexico, and now we are ready to expand into the U.S.”

Terms of Bioheart’s deal with the Ageless Regenerative Institute were not disclosed. The medical group mostly focuses on training physicians to extract adipose stem cells for use in cosmetic surgery.

Bioheart shares climbed 1 cent to close at 7 cents on Tuesday in heavier-than-normal trading volume. The 52-week high was 26 cents on July 22. The 52-week low was 4 cents on Friday.